The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
Open accessAbstract
Background: The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium–glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on kidney and cardiovascular events in participants with CKD with and without type 2 diabetes (T2D). This analysis reports the baseline characteristics of those recruited, comparing them with those enrolled in other trials. Methods: In DAPA-CKD, 4304 participants with a urinary albumin:creatinine ratio (UACR) ≥200 mg/g and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2 were randomized to dapagliflozin 10 mg once daily or placebo. Mean eGFR was 43.1 mL/min/1.73 m2 and median UACR was 949 mg/g (108 mg/mmol). Results: Overall, 2906 participants (68%) had a diagnosis of T2D and of these, 396 had CKD ascribed to a cause other than diabetes. The most common causes of CKD after diabetes (n = 2510) were ischaemic/hypertensive nephropathy (n = 687) and chronic glomerulonephritis (n = 695), of which immunoglobulin A nephropathy (n = 270) was the most common. A total of 4174 participants (97%) were receiving an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, 1882 (43.7%) diuretics, 229 (5.3%) mineralocorticoid receptor antagonists and 122 (2.8%) glucagon-like peptide 1 receptor agonists. In contrast to the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), the DAPA-CKD trial enrolled participants with CKD due to diabetes and to causes other than diabetes. The mean eGFR of participants in the DAPA-CKD trial was 13.1 mL/min/1.73 m2 lower than in CREDENCE, similar to that in the Finerenone in Reducing Kidney Failure and Disease Progression in DKD (FIDELIO-DKD) trial and the Study Of diabetic Nephropathy with AtRasentan (SONAR). Conclusions: Participants with a wide range of underlying kidney diseases receiving renin–angiotensin system blocking therapy have been enrolled in the DAPA-CKD trial. The trial will examine the efficacy and safety of dapagliflozin in participants with CKD Stages 2–4 and increased albuminuria, with and without T2D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationHeerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Self-citationIntensive supportive care plus immunosuppression in IgA nephropathy
Rauen, T., Eitner, F., Fitzner, C., Sommerer, C., Zeier, M., Otte, B., Panzer, U., Peters, H., Benck, U., Mertens, P. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1415463 · Cited by 726
Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency
Hou, F. F., Zhang, X., Zhang, G. H., Xie, D., Chen, P. Y., Zhang, W. R., Jiang, J. P., Liang, M., Wang, G. B., Liu, Z. R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053107 · Cited by 710
Self-citationvan Bommel, E. J. M., Muskiet, M. H. A., van Baar, M. J. B., Tonneijck, L., Smits, M. M., Emanuel, A. L., Bozovic, A., Danser, A. H. J., Geurts, F., Hoorn, E. J., et al. (2020) · Kidney International · doi:10.1016/j.kint.2019.09.013 · Cited by 363
Cherney, D. Z. I., Dekkers, C. C. J., Barbour, S. J., Cattran, D., Abdul Gafor, A. H., Greasley, P. J., Laverman, G. D., Lim, S. K., Di Tanna, G. L., Reich, H. N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30162-5 · Cited by 283 · cited 1×
“While small mechanistic studies have demonstrated that SGLT2 inhibitors exert physiological effects in people with non-DKD, including a characteristic haemodynamic ‘dip’ in GFR [9], the DAPA-CKD trial is the first to capture the effects on clinical kidney outcomes.”
BackgroundSelf-citationHerrington, W. G., Preiss, D., Haynes, R., von Eynatten, M., Staplin, N., Hauske, S. J., George, J. T., Green, J. B., Landray, M. J., Baigent, C., et al. (2018) · Clinical Kidney Journal · doi:10.1093/ckj/sfy090 · Cited by 237
Research works printed but not linked: 14
- Thomson, 2012, Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat, Am J Physiol Regul Integr Comp Physiol, 302, R75, 10.1152/ajpregu.00357.2011 · DOI · Paper page
- Cherney, 2014, Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus, Circulation, 129, 587, 10.1161/CIRCULATIONAHA.113.005081 · DOI · Paper page
- 1997, Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia), Lancet, 349, 1857, 10.1016/S0140-6736(96)11445-8 · DOI · Paper page
- Maschio, 1996, Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group, N Engl J Med, 334, 939, 10.1056/NEJM199604113341502 · DOI · Paper page
- Heerspink, 2020, Rationale and protocol of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial, Nephrol Dial Transplant, 35, 274, 10.1093/ndt/gfz290 · DOI · Paper page
- Heerspink, 2018, Rationale and protocol of the study of diabetic nephropathy with AtRasentan (SONAR) trial: a clinical trial design novel to diabetic nephropathy, Diabetes Obes Metab, 20, 1369, 10.1111/dom.13245 · DOI
- Lv, 2017, Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial, JAMA, 318, 432, 10.1001/jama.2017.9362 · DOI · Paper page
- Barratt, 2019, Implementing the kidney health initiative surrogate efficacy endpoint in patients with IgA nephropathy (the PROTECT trial), Kidney Int Rep, 4, 1633, 10.1016/j.ekir.2019.08.007 · DOI
- Heerspink, 2019, Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial, Lancet, 393, 1937, 10.1016/S0140-6736(19)30772-X · DOI · Paper page
- Lambers Heerspink, 2014, Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes with the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT, Am J Kidney Dis, 63, 244, 10.1053/j.ajkd.2013.09.016 · DOI · Paper page
- Sharma, 2013, The modern spectrum of renal biopsy findings in patients with diabetes, Clin J Am Soc Nephrol, 8, 1718, 10.2215/CJN.02510213 · DOI · Paper page
- Trachtman, 2018, DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS, J Am Soc Nephrol, 29, 2745, 10.1681/ASN.2018010091 · doi:10.1681/asn.2018010091
- Lazarus, 2018, Association of metformin use with risk of lactic acidosis across the range of kidney function: a community-based cohort study, JAMA Intern Med, 178, 903, 10.1001/jamainternmed.2018.0292 · DOI · Paper page
- Heerspink, 2018, Baseline characteristics and enrichment results from the SONAR trial, Diabetes Obes Metab, 20, 1829, 10.1111/dom.13315 · DOI
Cited by
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citation2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Self-citationKDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Self-citation10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s010 · Cited by 869
Wheeler, D. C., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Correa-Rotter, R., Rossing, P., Toto, R. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30369-7 · Cited by 556
Self-citation
Metadata
- Authors
- Wheeler, D. C., Stefansson, B. V., Batiushin, M., Bilchenko, O., Cherney, D. Z. I., Chertow, G. M., Douthat, W., Dwyer, J. P., Escudero, E., Pecoits-Filho, R., Furuland, H., Górriz, J. L., Greene, T., Haller, H., Hou, F. F., Kang, S.-W., Isidto, R., Khullar, D., Mark, P. B., McMurray, J. J. V., Kashihara, N., Nowicki, M., Persson, F., Correa-Rotter, R., Rossing, P., Toto, R. D., Umanath, K., Van Bui, P., Wittmann, I., Lindberg, M., Sjöström, C. D., Langkilde, A. M., & Heerspink, H. J. L.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-08-30
- Volume
- 35
- Issue
- 10
- Pages
- 1700-1711
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W3081745704
- Cited by
- 194
- References
- 12
- FWCI
- 16.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- AstraZeneca
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. https://app.cochat.ai/papers/10.1093/ndt/gfaa234
- The paper
- Wheeler, D. C., Stefansson, B. V., Batiushin, M., Bilchenko, O., Cherney, D. Z. I., Chertow, G. M., Douthat, W., Dwyer, J. P., Escudero, E., Pecoits-Filho, R., Furuland, H., Górriz, J. L., Greene, T., Haller, H., Hou, F. F., Kang, S.-W., Isidto, R., Khullar, D., Mark, P. B., . . . Heerspink, H. J. L. (2020). The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfaa234
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.